Bajaj Healthcare launches Posaconazole API for treatment of black fungus

Pharma company Bajaj Healthcare (BHL) has announced the launch of Posaconazole API, a medication that will be used in the treatment of mucormycosis or Black Fungus infection.
BHL has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market Posaconazole API as approved medication for treating Mucormycosis in India.
The commercial production of the API is expected to begin in the first week of June and it will be marketed in the domestic as well as overseas market.
It will be available as a prescription-based medication, with recommended doses.
According to doctors, the fungal infection that has emerged during the second wave has been widely linked with excessive usage of steroids and uncontrolled diabetes in coronavirus positive patients.
It is expected that the availability of an effective treatment such as Posaconazole will considerably ease the pressure and offer patients much needed and timely therapy option.
India has asked its missions abroad to source Amphotericin-b, an anti-fungal drug, as the number of black fungus infections in patients who recovered from Covid-19 rise.
More than 11,000 cases of black fungal infection have been reported from different parts of the country so far.
The infection causes blackening or discolouration over the nose, blurred or double vision, chest pain, breathing difficulties and coughing blood.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.